A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

Patients receive 10 units of HIV-1 immunogen in IFA or IFA alone every 12 weeks, then are followed for 104-148 weeks.

Inclusion criteria

Concurrent Medication:

Allowed:

• Antiretrovirals if on a stable dose for at least the past 3 months.

Patients must have:

• HIV-1 infection with CD4 count 300-549 cells/mm3.
• No AIDS-defining condition.
• Been on a stable dose of antiretroviral for the past 3 months, if taking antiretrovirals.

NOTE:

• KS is permitted if not requiring systemic therapy.

Prior Medication:

Allowed:

• Prior antiretrovirals.

Exclusion criteria

Concurrent Medication:

Excluded:

• Systemic chemotherapy for KS.
• Treatment for malignancy other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

Patients with the following prior conditions are excluded:

• History of any illness that would interfere with study.
• Acute infection requiring prescription therapy within the past month, other than genital herpes and oral or vaginal candidiasis.

Prior Medication:

Excluded:

• Prior HIV-1 Immunogen. Unwilling to use effective safe sex practices. Active substance abuse.